Insmed(INSM) - 2023 Q4 - Annual Results

Exhibit 99.1 Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update —Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second- Quarter 2024 Ahead of the ASPEN Readout— —Company Ends 2023 With $780 Million of Cash, Cash Equivalents, and M ...